Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
MPS I
Disease Information
History
Genetics
Molecular basis
Signs, Symptoms & Clinical Presentation
Diagnosis
Management of MPS I Disease
Medical Information Services
MPS I Registry
Practical Info
Request Materials
Pompe

 



 

Signs, Symptoms & Clinical presentation

MPS I is a heterogeneous disease spanning a spectrum of severity. Individuals with the most severe form of MPS I typically suffer from a number of progressively debilitating symptoms, including mental retardation. Their maximum lifespan is approximately 8 to 10 years[1]. Individuals at the opposite end of the disease spectrum have physical symptoms that can be as severe, but they generally retain normal intellect and stature, and may have a normal lifespan.

Because the disease generally affects many organ systems and can present in a variety of ways, diagnosis and treatment of MPS I disease may require collaboration and communication among geneticists, neurologists, pediatricians, developmental specialists, surgeons, cardiologists, gastroenterologists, physiotherapists, and primary care providers.

General physical appearance

The physical appearance for MPS I is quite variable:

Coarse facial features
Broad mouth, square jaw, and receding chin
Large tongue
Excess facial and body hair
Large, scaphocephalic head
Corneal clouding
Short neck
Stocky build with short trunk
Joint deformities (see picture below)


Claw hand deformity in a patient with MPSI
(Photo courtesy of National MPS)


Patient with MPS I at age 4 years
(Photos courtesy of the National MPS Society, Inc.)

Specific manifestations

References

1. Neufeld, E.F., and Muenzer, J. (1995) The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. (eds.). 7th edition. McGraw-Hill, Medical Publishing Division, pp. 2465.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease